Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) was downgraded by Jefferies Financial Group from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, The Fly reports. They currently have a $4.00 price objective on the stock. Jefferies Financial Group’s target price points to a potential upside of 25.79% from the company’s previous close.
Other equities analysts also recently issued research reports about the company. Morgan Stanley dropped their price objective on Centessa Pharmaceuticals from $19.00 to $15.00 and set an “overweight” rating on the stock in a report on Tuesday, May 24th. The Goldman Sachs Group dropped their price objective on Centessa Pharmaceuticals from $12.00 to $8.00 and set a “neutral” rating on the stock in a report on Tuesday, May 24th. Finally, Zacks Investment Research upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 19th.
Shares of CNTA opened at $3.18 on Friday. The business’s 50-day moving average is $7.25 and its 200-day moving average is $9.06. Centessa Pharmaceuticals has a fifty-two week low of $2.88 and a fifty-two week high of $26.90. The company has a market capitalization of $299.05 million and a price-to-earnings ratio of -1.34. The company has a debt-to-equity ratio of 0.16, a current ratio of 21.37 and a quick ratio of 21.37.
In other Centessa Pharmaceuticals news, EVP Antoine Yver sold 20,222 shares of the company’s stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $5.42, for a total transaction of $109,603.24. Following the completion of the sale, the executive vice president now owns 813,675 shares of the company’s stock, valued at $4,410,118.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.09% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Centessa Pharmaceuticals by 146.7% in the fourth quarter. JPMorgan Chase & Co. now owns 4,509 shares of the company’s stock valued at $51,000 after acquiring an additional 2,681 shares during the period. Bank of America Corp DE bought a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $54,000. Compagnie Lombard Odier SCmA boosted its position in shares of Centessa Pharmaceuticals by 111.6% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 5,820 shares of the company’s stock valued at $66,000 after acquiring an additional 3,070 shares during the period. Northern Trust Corp bought a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $100,000. Finally, Prelude Capital Management LLC bought a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at approximately $102,000. 95.72% of the stock is owned by institutional investors.
Centessa Pharmaceuticals Company Profile (Get Rating)
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.
- Get a free copy of the StockNews.com research report on Centessa Pharmaceuticals (CNTA)
- Two Consumer Staples With Bright Outlook For Dark Times
- Datadog: A Unicorn Cloud Stock
- 3 Precious Metals ETFs to Play the Commodities Boom
- Cisco Systems Stock is Enroute Higher
- Affirm Holdings Stock: Buy Now, Gain Later
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.